Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media

N/ACompletedNCT00195611

Wyeth is now a wholly owned subsidiary of Pfizer3,293 enrolled

Overview

The aim of this study is to assess in France the impact of Prevenar on the possible evolution of the pneumococcal serotypes distribution and antibiotic resistance in NP samples of children with AOM.

Study Type

OBSERVATIONAL

Enrollment

3,293

Conditions

Otitis Media Otitis Media With Effusion Pneumococcal Infections

Interventions

PrevenarDRUG

Eligibility

Sex: ALLMin age: 6 MonthsMax age: 24 Months

Medical Language ↔ Plain English

Inclusion Criteria: * Infants aged from 6 to 24 months * Presenting with AOM (ear infection) * Patients must not have received any antibiotic therapy within the past 7 days. Other inclusion applies. Exclusion Criteria:

Locations (35)

Unnamed facility

Auch, France

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.